Exclusive or non-exclusive distribution rights: how to decide

Almost every distributor will ask for exclusivity, for the whole country, at the first meeting. It is a reasonable thing for them to want. Whether you should give it depends on questions most manufacturers have not asked yet.

Why they ask, and why the ask is fair

A distributor who takes on your product is spending money before they earn any: registration, in many markets, plus stock, training, demo units, and time from salespeople who could be selling something established. If a competitor can appear six months later and sell the same device into the accounts they opened, that investment is at risk.

So the request is not a negotiating trick. The problem is that exclusivity is usually granted at the moment you know least — before the first order, on the strength of a few meetings — and it is the hardest term to take back.

What exclusivity actually costs you

The market moves at their pace. If they are slow, you are slow, and you have no second route while the agreement runs.
You lose the comparison. With one partner you never learn whether the result reflects the market or the partner. A second one in the same country is uncomfortable, but it is information.
It compounds with the registration. In markets where the partner holds the registration, exclusivity plus registration control means they hold both the route to market and the legal right to it. That is a lot of leverage on one side of a table.
Underperformance becomes a legal question. Without minimums, "they are not selling much" is an opinion. With minimums, it is a fact you can act on.

The questions that decide it

How much do they have to invest before they earn anything?

This is the strongest argument in their favour. If the partner is funding registration, holding stock, and putting people through training on a product that needs clinical explanation, exclusivity is a fair exchange for that risk. If they are adding a catalogue line and waiting for orders, it is not.

Can they actually cover the country?

Many markets are two or three distinct commercial territories rather than one. A partner strong in the capital may reach the second city through sub-distributors they do not control, and the rest not at all. Exclusivity over places they cannot serve is the most common version of this mistake.

Is your product a lead line or a filler?

If your device or assay is one of forty in the bag, exclusivity means very little activity is guaranteed. If it is something they will build a specialist team around, it means a great deal.

What does the market's structure allow?

Where the registration is held locally and is difficult to transfer, exclusivity is a bigger commitment than the contract term suggests — the practical cost of switching is measured in the months of re-registration, not in the notice period.

Decide this with the field in front of you

Whether exclusivity makes sense depends on who else could carry the product. We can show you that before you commit.

Request a demo →

The middle options most agreements ignore

The choice is rarely all or nothing, and the useful structures sit in between:

Exclusivity with minimums. The standard answer. It only works if the minimums are real, agreed in units rather than intentions, and if there is a defined consequence — usually conversion to non-exclusive rather than termination, which is easier to enforce and less catastrophic for both sides.
Exclusivity that has to be earned. Non-exclusive for the first year, converting on performance. Attractive to a serious partner and unattractive to one who wants to park the line.
Exclusivity by territory. The capital region to one partner, other regions open or assigned separately. Common in large or geographically split markets.
Exclusivity by channel. Private hospitals to one partner, public tender to another. This suits markets where the two require genuinely different capabilities.
Exclusivity by product line. Particularly useful across devices and IVDs, where the buyer inside the hospital is a different person and the partner good at one may have no access to the other.

If you do grant it

Three things belong in the agreement, and they are much easier to include at the start than to add later:

Minimums with a defined consequence, reviewed on a stated date, in units rather than revenue so currency movement does not do the arguing for either side.
A registration transfer clause. What happens to the registration on termination, who cooperates with what, and by when. This is the clause that determines how expensive a mistake is to correct.
A reporting obligation. Sell-through and the accounts opened, not just what they bought from you. Without it you cannot tell a slow market from a slow partner until it is very late.